Rezolute, Inc. Common Stock (NV)

Rezolute, Inc., a rare disease company focused on treating hyperinsulinism, announced it will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference (May 19, 2026) and the Jefferies Global Healthcare Conference (June 2-4, 2026). The company will present oral results from its Phase 3 sunRIZE study of ersodetug in patients wit...

Rezolute, Inc. (NASDAQ: RZLT) experienced a severe stock price collapse of 87.2% on December 19, 2025, following the announcement that its lead drug candidate ersodetug failed to meet primary and key secondary endpoints in the Phase 3 sunRIZE clinical trial for congenital hyperinsulinism. The drug failed to demonstrate statistically significant e...

XOMA Royalty Corporation reported over $50 million in cash receipts for 2025, with royalties up 68% year-over-year. The company added 22 assets to its portfolio, completed seven acquisitions generating $11.7 million in non-dilutive capital, and repurchased 648,048 shares for $16 million. Key 2026 catalysts include Phase 2b/3 data readouts and pot...

Rezolute, Inc., a late-stage rare disease company developing ersodetug antibody therapy for hyperinsulinism-induced hypoglycemia, announced it will participate in the Citizens Life Sciences Conference on March 10-11, 2026, in Miami, FL, with management available for one-on-one investor meetings.

Rezolute, Inc. (NASDAQ: RZLT) experienced a dramatic 90% intraday stock price decline on December 11, 2025, after announcing that its Phase 3 sunRIZE trial for ersodetug failed to meet primary and secondary endpoints for treating hypoglycemia caused by hyperinsulinism. The failure contradicted the company's previous assurances about the drug's ef...